Metapristone (RU486-derivative) inhibits endometrial cancer cell progress through regulating miR-492/Klf5/Nrf1 axis
Authors:
Open Access
- 7 January 2021
- journal article
- research article
- Published by Springer Nature in Cancer Cell International
- Vol. 21 (1) , 1-14
Abstract
Background: Endometrial cancer is an invasive gynecological cancer prevalent in the world. The pathogenesis of endometrial cancer is related to multiple levels of regulation, referring to oestrogen, tumor-suppressor gene (e.g.PTEN) or microRNAs (e.g. miR-23a and miR-29b). Metapristone is a hormone-related drug, which is widely used in clinical treatment of endometrial cancer. However, the underlying regulatory mechanism of metapristone on endometrial cancer is still unclear, especially the regulatory effect on microRNAs. The aim of this study is to investigate the specific molecular mechanism of metapristone regulating microRNAs in the treatment of endometrial cancer.Methods: RL95-2 cells and Ishikawa cells were used as the endometrial cancer models. MiR-492 or si-miR-492 was transfected into RL95-2 cells and Ishikawa cells to explore the role of miR-492 in endometrial cancer. The cell cancer model and mice cancer model were used to confirm the function and mechanism of metapristone affected on endometrial cancer in vitro and in vivo. Mechanically, cell proliferation was monitored using MTT assay, cell colony formation assay and EdU assay. Luciferase reporter assay was used to identify the downstream target gene of miR-492. The protein expression and RNA expression were respectively measured by western blot and qRT-PCR for cell signaling pathway research, subsequently, were verified in the mice tumor model via immunohistochemistry.Results: Metapristone as a kind of hormone-related drug significantly inhibited the endometrial cancer cell growth through regulating cell apoptosis-related gene expression. Mechanically, miR-492 and its target genesKlf5andNrf1were highly expressed in the endometrial cancer cell lines, which promoted cell proliferation and inhibited cell apoptosis. Metapristone decreased the expression of miR-492 and its target genesKlf5andNrf1, leading to endometrial cancer cell growth inhibition in vitro and in vivo.Conclusion: Metapristone inhibited the endometrial cancer cell growth through regulating the cell apoptosis-related signaling pathway and decreasing the expression of miR-492 and its downstream target genes (Klf5andNrf1), which provided the theoretical basis in clinical treatment of endometrial cancer.Keywords
All Related Versions
Funding Information
- Natural Science Foundation of Beijing Municipality (7184211)
- National Natural Science Foundation of China (81801402)
- Beijing Natural Science Foundation Program and Scientific Research Key Program of Beijing Municipal Commission of Education (KM201610025023)
- Beijing key clinical specialty project
This publication has 51 references indexed in Scilit:
- A novel UPLC/MS/MS method for rapid determination of metapristone in rat plasma, a new cancer metastasis chemopreventive agent derived from mifepristone (RU486)Journal of Pharmaceutical and Biomedical Analysis, 2014
- The Unique Pharmacological Characteristics of Mifepristone (RU486): From Terminating Pregnancy to Preventing Cancer MetastasisMedicinal Research Reviews, 2014
- The Effect of Mifepristone (RU486) on the Endocannabinoid System in Human Plasma and First-Trimester Trophoblast of Women Undergoing Termination of PregnancyThe Journal of Clinical Endocrinology & Metabolism, 2014
- Synthesis, Spectral Characterization, and In Vitro Cellular Activities of Metapristone, a Potential Cancer Metastatic Chemopreventive Agent Derived from Mifepristone (RU486)The AAPS Journal, 2014
- Mechanism of the reversal effect of mifepristone on drug resistance of the human cervical cancer cell line HeLa/MMCGenetics and Molecular Research, 2014
- The double life of KLF5: Opposing roles in regulation of gene-expression, cellular function, and transformationIUBMB Life, 2013
- Control of metastatic progression by microRNA regulatory networksNature Cell Biology, 2013
- Endometrial CancerObstetrics & Gynecology, 2012
- Endometrial cancerThe Lancet, 2005
- Mifepristone Induces Growth Arrest, Caspase Activation, and Apoptosis of Estrogen Receptor-Expressing, Antiestrogen-Resistant Breast Cancer CellsClinical Cancer Research, 2004